MarketCap
Facebook
X
Telegram
Zai Lab Limited Total Liabilities | ZLAB
Annual Total Liabilities Zai Lab Limited
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 457 M | 345 M | 240 M | 175 M | 230 M | 128 M | 60.5 M | 50.9 M | 14.5 M | 140 M | 32.3 M | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 457 M | 14.5 M | 170 M |
Quarterly Total Liabilities Zai Lab Limited
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 461 M | 468 M | 434 M | 457 M | 399 M | 372 M | 363 M | 345 M | 318 M | 283 M | 226 M | 240 M | 163 M | 174 M | 169 M | 175 M | 193 M | 207 M | 193 M | 230 M | 140 M | 224 M | 122 M | 128 M | 128 M | 82.7 M | 128 M | 60.5 M | 54.5 M | - | - | 50.9 M | - | - | - | 14.5 M | - | - | - | 5.95 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 468 M | 5.95 M | 219 M |
Total Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Repare Therapeutics
RPTX
|
25.4 M | - | - | $ 112 M |  Canada |
 |
Sesen Bio
SESN
|
58.4 M | - | 7.29 % | $ 127 M |  USA |
 |
Windtree Therapeutics
WINT
|
14.7 M | - | - | $ 26.8 M | USA |
 |
Trean Insurance Group
TIG
|
1.27 B | - | - | $ 316 M | USA |
 |
SQZ Biotechnologies Company
SQZ
|
42.8 M | - | 57.95 % | $ 12.8 M | USA |
 |
MEI Pharma
MEIP
|
1.07 M | - | 10.43 % | $ 20.5 M | USA |
 |
Palatin Technologies
PTN
|
1.84 M | - | - | $ 13 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
1.1 B | - | - | - |  Russia |
 |
Lyra Therapeutics
LYRA
|
46.8 M | - | - | $ 24.9 M | USA |
 |
Brickell Biotech
BBI
|
4.81 M | - | -5.38 % | $ 6.06 M | USA |
 |
Applied Therapeutics
APLT
|
29.7 M | - | - | $ 8.42 M | USA |
 |
ESSA Pharma
EPIX
|
3.51 M | - | - | $ 8.86 M | Canada |
 |
Generation Bio Co.
GBIO
|
145 M | - | - | $ 344 M | USA |
 |
Clearside Biomedical
CLSD
|
64 M | - | - | $ 25.3 M | USA |
 |
Merus N.V.
MRUS
|
135 M | - | - | $ 5.78 B |  Niderland |
 |
RAPT Therapeutics
RAPT
|
50.4 M | - | - | $ 2.36 B | USA |
 |
Annexon
ANNX
|
65.9 M | $ 4.2 | -0.71 % | $ 651 M | USA |
 |
AbbVie
ABBV
|
97.3 B | $ 293.87 | 0.19 % | $ 520 B | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
4.18 B | $ 151.6 | -3.2 % | $ 19.9 B | USA |
 |
Galmed Pharmaceuticals Ltd.
GLMD
|
8.23 M | $ 4.63 | 21.05 % | $ 20 M |  Israel |
 |
Avenue Therapeutics
ATXI
|
1.1 M | - | -52.27 % | $ 4.45 M | USA |
 |
Axon Enterprise
AXON
|
3.76 B | $ 302.6 | -0.19 % | $ 23.6 B | USA |
 |
Theratechnologies
THTX
|
78.6 M | - | - | $ 83.9 M | Canada |
 |
Liquidia Corporation
LQDA
|
283 M | $ 51.37 | 7.31 % | $ 4.42 B | USA |
 |
CRISPR Therapeutics AG
CRSP
|
343 M | $ 45.05 | -9.97 % | $ 4.05 B |  Schweiz |
 |
Scholar Rock Holding Corporation
SRRK
|
159 M | $ 48.48 | -5.96 % | $ 5.56 B | USA |
 |
Geron Corporation
GERN
|
345 M | $ 0.96 | -3.71 % | $ 640 M | USA |
 |
Bristol-Myers Squibb Company
BMY
|
71.5 B | $ 62.8 | 1.06 % | $ 128 B | USA |
 |
Titan Pharmaceuticals
TTNP
|
483 K | - | -3.76 % | $ 3.47 M | USA |
 |
Kazia Therapeutics Limited
KZIA
|
14.4 M | $ 7.4 | -0.13 % | $ 113 M |  Australia |
 |
Celldex Therapeutics
CLDX
|
55.8 M | $ 30.68 | -1.81 % | $ 2.04 B | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
4.7 M | $ 4.0 | -6.76 % | $ 48.8 M | Israel |
 |
Allena Pharmaceuticals
ALNA
|
15.9 M | - | 3.16 % | $ 1.9 M | USA |
 |
Ligand Pharmaceuticals Incorporated
LGND
|
543 M | $ 317.26 | 0.99 % | $ 6.14 B | USA |
 |
Eli Lilly and Company
LLY
|
36.6 B | $ 1 432.7 | 1.47 % | $ 1.29 T | USA |
 |
TCR2 Therapeutics
TCRR
|
67.4 M | - | - | $ 58.1 M | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
134 M | $ 84.95 | 0.13 % | $ 7.99 B | USA |
|
TFF Pharmaceuticals
TFFP
|
2.46 M | - | -60.05 % | $ 125 K | USA |
 |
Mesoblast Limited
MESO
|
187 M | $ 14.0 | -3.06 % | $ 16.9 B | Australia |
 |
CorMedix
CRMD
|
421 M | $ 5.37 | -2.1 % | $ 387 K | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
234 M | - | -15.15 % | $ 60.3 M |  Britain |
 |
MannKind Corporation
MNKD
|
843 M | $ 4.22 | 0.84 % | $ 1.29 B | USA |
 |
AVEO Pharmaceuticals
AVEO
|
59.5 M | - | - | $ 521 M | USA |
 |
MediciNova
MNOV
|
4.02 M | $ 1.4 | -4.76 % | $ 68.7 M | USA |
 |
Merck & Co.
MRK
|
58.4 B | $ 147.75 | -0.68 % | $ 370 B | USA |
 |
Moderna
MRNA
|
3.69 B | $ 250.79 | -6.77 % | $ 97.6 B | USA |
 |
Axcella Health
AXLA
|
14.8 M | - | -16.42 % | $ 249 M | USA |